Advanced in Exogenous Lipoid Pneumonia

Peggy Jacques

Gent, VLG, BE 
Advanced in Exogenous Lipoid Pneumonia
Gent, VLG, BE 
OverviewLocationsClinical Research

Overview

Peggy Jacques practices in Gent, Belgium. Ms. Jacques is rated as an Advanced expert by MediFind in the treatment of Exogenous Lipoid Pneumonia. Her top areas of expertise are Arthritis, Rheumatoid Arthritis (RA), Exogenous Lipoid Pneumonia, and Axial Spondyloarthritis (AxSpA).

Her clinical research consists of co-authoring 40 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Exogenous Lipoid Pneumonia.

Gender
Female

Locations

Gent, VLG, Belgium
Other Locations
Zwijnaarde, VLG, Belgium
Belgian Defence
Brussels, BRU, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: November 17, 2025
Intervention Type: Drug
Study Drug: ABX464
Study Phase: Phase 2
Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Enrollment Status: Completed
Publish Date: February 15, 2023
Intervention Type: Drug
Study Drugs: ABX464, Methotrexate
Study Phase: Phase 2
Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)
Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)
Enrollment Status: Completed
Publish Date: September 27, 2019
Intervention Type: Other
View 2 Less Clinical Trials

40 Total Publications

Cigarette smoke-primed citrullinated HLA-DR4 T cell reactivity is modulated by γδ-T cells.
Cigarette smoke-primed citrullinated HLA-DR4 T cell reactivity is modulated by γδ-T cells.
Journal: Annals of the rheumatic diseases
Published: July 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Jacques's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile